Overcoming Bottlenecks in Quantifying Oligonucleotide Therapeutics: Using LC-MS/MS Technology and Expertise to Reduce Risk and Increase Your Speed to Market Developing bioanalytical solutions to support oligonucleotide drug programs can be challenging due to the unique physicochemical properties of these molecules. This whitepaper outlines both the established and the unique liquid chromatography and extraction technologies Covance has developed to ensure you remain at the forefront of oligonucleotide innovation. Learn how you can benefit from the workflows to: eliminate bottlenecks and accelerate timelines with state-of-the-art liquid chromatography, focused detection and extraction technologies that generate accurate and robust data, rapidly receive the results you need through world-class scientific expertise based on decades of experience in solving complex bioanalytical challenges and capitalize on the rapidly expanding oligonucleotide marketing with the support of technologies and expertise.

Exploratory and preclinical studies often require rapid development of assays. In creating novel immunoassays or providing cellular-based analysis, researchers must proactively plan for a transition to CAP/CLIA or GxP facility for qualification, method validation and implementation. These case studies showcase a number of challenging, high-profile projects supported by the Covance Translational Biomarker Solutions (Covance TBS) team.

In the rapidly evolving Chinese research and development (R&D) landscape, there are several key considerations for effectively supporting global clinical trials with regulated bioanalysis in China. This white paper discusses the current status of bioanalysis in the region, in-country support and local guidance strategies to combat potential challenges in supporting clinical bioanalysis within China.

Learn from three thought leaders in the field of immunotherapy as they share their knowledge on trends and advances across the entire spectrum of development.